Abstract. Disturbances in magnesium homeostasis, often linked to altered expression and/or function of magnesium channels, have been implicated in a plethora of diseases. This review focuses on magnesium transporter 1 (MAGT1), as recently described changes in this gene have further extended our understanding of the role of magnesium in human health and disease. The identification of genetic changes and their functional consequences in patients with immunodeficiency revealed that magnesium and MAGT1 are key molecular players for T cell-mediated immune responses. This led to the description of XMEN (X-linked immunodeficiency with magnesium defect, Epstein Barr Virus infection, and neoplasia) syndrome, for which Mg 2+ supplementation has been shown to be beneficial. Similarly, the identification of a copy-number variation (CNV) leading to dysfunctional MAGT1 in a family with atypical ATRX syndrome and skin abnormalities, suggested that the MAGT1 defect could be responsible for the cutaneous problems. On the other hand, recent genetic investigations question the previously proposed role for MAGT1 in intellectual disability. Understanding the molecular basis of the involvement of magnesium and its channels in human pathogenesis will improve opportunities for Mg 2+ therapies in the clinic.
The magnesium ion (Mg 2+ ) is universally recognized as essential for key functions, both at the cellular and systemic levels. Indeed, magnesium has an important role in the pathophysiology of the brain, heart and vasculature, lung, and skeletal muscles, to cite but a few, and it has been considered as a treatment for several major diseases including pre-eclampsia, stroke, myocardial infarction, and asthma in several large-scale clinical trials [1] . However, the molecular mechanisms underlying the effects of magnesium in so many different tissues are still largely unknown.
Ion homeostasis is strictly dependent on efficient regulation of ionic transport across cellular membranes. As a consequence, it is not surprising that the pathogenesis of an ever-increasing number of human diseases seems to lie in the disturbed function of ion channels and/or accessory regulatory proteins [2] . Analogously, the molecular characterization of magnesium-specific channels and the discovery of novel human genetic disorders ascribable to magnesium disturbances have been advancing at the same pace, fostering a deeper understanding of known magnesium physiology and shedding light on previously unsuspected functions reaching far beyond ion homeostasis.
The identification of genetic disorders affecting systemic magnesium homeostasis, i.e. causing hypomagnesemia, has greatly enhanced our knowledge of the mechanisms regulating Mg 2+ (re)absorption in the kidney and intestine. Hypomagnesemia with secondary hypocalcemia (HSH; OMIM 602014) and isolated autosomal recessive hypomagnesemia (IRH; OMIM 611718) have shown the transient receptor potential type melastatin (TRPM)-6 channel as the gatekeeper that controls the body's magnesium balance [3] .
Yet, ion channels often exhibit unforeseen properties in vivo because of their interaction with a variety of signaling/scaffolding proteins that can influence their coupling to intracellular second messengers and pathways. Hence, ion channels can exert functions that transcend their ionconducting roles. Magnesium channels are no less so. Common single nucleotide polymorphisms (SNPs) in the TRPM6 gene are associated with an increased risk of developing type 2 diabetes mellitus [4] . The highly homologous TRPM7 channel has been implicated in the progression of several types of cancer [5] , and in the pathogenesis of some neurodegenerative diseases [6] . The Na + /Mg 2+ exchanger solute carrier SLC41A1 seems to be involved in the development of Parkinson's disease, nephronophthisis and preeclampsia [7] . This review will focus on magnesium transporter 1 (MAGT1), as recently described genetic changes [8, 9] have further expanded our understanding of the role of magnesium in human disease.
MAGT1 in cellular and animal studies
MAGT1 was originally identified in an oligonucleotide microarray screen for genes up-regulated in mouse kidney distal convoluted tubule cells under low Mg 2+ growth conditions [10] . MAGT1 is widely expressed and evolutionary conserved, but has no structural similarity to any known bacterial, yeast, or mammalian Mg 2+ transport proteins; yet it can complement the Mg 2+ -deficiency phenotype shown by mutants lacking other Mg 2+ channels [11, 12] . It localizes to the plasma membrane and mediates a voltagedependent, Mg 2+ transport in a very selective way [13] . Independent studies have confirmed modulation of MAGT1 by extracellular Mg 2+ availability, and supported the hypothesis that the protein has a role in cellular Mg 2+ homeostasis, as knockdown of MAGT1 protein significantly lowers the total and free intracellular Mg 2+ concentrations in mammalian cell lines [11] . MAGT1 has a human gene paralogue, the tumor suppressor candidate TUSC3 (GeneBank AAH10370.1), first identified as a putative tumor suppressor gene in prostate cancer [14] . TUSC3 shares 66% identity with MAGT1 and was similarly found to mediate cellular Mg 2+ uptake and vertebrate development [11] ; however, it is more permissive in substrate specificity and has a more limited tissue distribution [13] . Both MAGT1 and TUSC3 were initially proposed to be oligosaccharyltransferase (OST) subunits based upon homology to the yeast Ost3 and Ost6 proteins [15] . A recent study [16] provides new evidence in support of this hypothesis, raising the possibility that the link between MAGT1 or TUSC3 expression and magnesium homeostasis might occur by an indirect mechanism involving glycosylation of a protein that is needed for Mg 2+ transport activity. The Drosophila orthologue of human MAGT1 and TUSC3 (CG7830) displays a sequence similarity of 72% to human MAGT1, and the protein is functionally upregulated by protein kinase C [17] . Knockdown of CG7830 causes aberrant eye morphology, which likely implies a defect in neuronal transmission [18] .
MAGT1 in humans
MAGT1 (OMIM 300715) is located on human chromosome X, band Xq21.1 (base pairs 77,826,364 to 77,895,593 (GRCh38/hg38), and consists of 10 exons (69.4 kb). There are three protein coding isoforms of MAGT1 coding for 367 (isoform 201), 355 (isoform 004) and 134 (isoform 002) amino acids [19, 20] (figure 1). Based on different transmembrane (TM) prediction methods, MAGT1 could contain four to five TM domains [10, 11] , but recent studies are more in agreement with the former model [21] . A large amino-terminal segment possesses a predicted signaling sequence, and a small carboxy-terminal tail displays phosphorylation consensus sites. The protein contains the oligosaccharyltransferase subunit and a thioredoxin-like fold. In humans, loss-of-function mutations in MAGT1 have been shown to cause an immune deficiency called "X-linked immunodeficiency with magnesium defect, Epstein Barr virus infection, and neoplasia" (XMEN) [20] . MAGT1 mutations have also been associated with intellectual disability and skin disorders [8, 22] (table 1) .
MAGT1 and immunodeficiency
Magnesium has long been recognized as an important modulator of immunity, despite a poor understanding of the underlying molecular mechanisms. It is well known that in animal models, Mg 2+ deficiency induces a clinical inflammatory syndrome characterized by leukocyte and macrophage activation, release of inflammatory cytokines and acute phase proteins, and excessive production of free radicals [23] . Moreover, Mg 2+ influences acquired immunity by regulating the proliferation and development of lymphocytes [24] . The recent discovery of XMEN disease showed that magnesium, and in particular the MAGT1 channel, are key molecular players for T cell activation and cytotoxic activity.
XMEN was first identified during chromosome X specific exome sequencing in three males from 2 families [9] . They had immunodeficiency characterized by CD4 + lymphopenia, severe chronic viral infections and defective T cell activation. An additional five patients have been identified after screening; they had chronic Epstein Barr Virus (EBV) infection and splenomegaly, and developed (apart from the youngest patient) various EBV-associated B-cell lymphoproliferative disorders [19, 25, 26] . The patients were developmentally normal. XMEN disease is phenotypically heterogeneous, as the clinical presentations are somewhat different at varying ages (3 to 58 years). The causative MAGT1 mutations resulted in loss of function due to nonsense, splicing or frameshift mutations, which led to nonsense-mediated decay of the mRNA, and deficient gene expression [19, 26] (table 1) . The severity of the phenotype does not seem to correlate with the type of mutation and its location. Extensive investigations of immune cell function in XMEN patients established the key role of MAGT1 in T lymphocytes and natural killer (NK) cell activation (figure 2). Li et al. [9] showed that upon CD4 + T-cell receptor stimulation, MAGT1 mediates a transient Mg 2+ influx that is necessary for phospholipase C gamma 1 (PLC␥1) activation, which drives the subsequent Ca 2+ rise and downstream signaling. In XMEN patients, loss-of-function mutations of MAGT1 lead to delayed PLC␥1 activation and eventually to weakened CD4 + lymphocyte activation. In addition, it was demonstrated that the intracellular free Mg 2+ concentration is important for proper function of cytotoxic CD8 + T lymphocytes (CTLs) and natural killer (NK) cells: the decreased basal intracellular Mg 2+ levels found in XMEN patients cause defective expression of the NKactivating receptor NKG2D in NK cells and CTLs [25] . NKG2D is involved in antiviral and antitumor cytotoxicity [27] ; thus, loss of NKG2D due to loss of MAGT1 function impairs cytolytic responses against EBV and may predispose to the development of lymphoma. Remarkably, magnesium supplementation in MAGT1-deficient 
MAGT1 and intellectual disability
Neuronal Mg 2+ concentrations are of major importance in the regulation of N-methyl-D-aspartate (NMDA) receptor excitability, which is responsible for synaptic transmission, neuronal plasticity and excitotoxicity [28] . Indeed, magnesium supplementation improves learning and memory function in mice [29] . Magnesium deficiency has been associated with a wide range of neurological pathologies; although most reports are of an epidemiological nature, this suggests a possible etiopathogenetic role for magnesium [1] . Not surprisingly, genetic changes in magnesium channels also seem to impact on brain function. Carriers of TRPM6 mutations leading to hypomagnesemia with secondary hypocalcemia (HSH) are affected by immunodeficiency (ID); in addition, TRPM6-null mice show neural tube defects [30] . A TRPM7 variant has been associated with neurodegenerative disorders [31] ; moreover TRPM7 is required for differentiation and function of dopaminergic neurons in zebrafish [32] . An SNP in the gene coding for the Mg 2+ exporter SLC41A1 results in gain of function and has been linked to Parkinson's disease [33] .
A possible association between MAGT1 and ID was suggested by homology with TUSC3, which has been implicated in autosomal recessive ID in several reports [34] . The link was first ascribed to the putative N-glycosylation activity of TUSC3 and MAGT1 [35] . Defects in N-glycosylation have been identified in congenital disorders of glycosylation (CDG) syndromes, which are characterized by developmental delay, ataxia, seizures, retinopathy, fibrosis, coagulopathies, failure to thrive, dysmorphic features, cerebellar atrophy and ocular abnormalities [36] . However, glycosylation analysis of fibroblasts from patients bearing TUSC3 mutations showed normal N-glycan synthesis and transfer, suggesting that the ID could rather be ascribed to other functions of the protein, possibly Mg 2+ uptake [34] . The first genetic change in MAGT1 that was associated to ID was a missense mutation (c.932T>G, p.V311G). It was identified in a family with X-linked nonsyndromic ID after a systematic, high-throughput mutational sequence screen of the VEGA-annotated X chromosome gene set (737 genes) was performed in 250 ID Australian families [22] . This variant, resulting in the substitution of a highly conserved amino acid, segregated with affected males, but was not found in 267 control X chromosomes. However, the functional consequences of the mutation were not assessed, and no further affected individuals have been identified since then.
In contrast to this report, a recent analysis strongly questioned the role of the p.V311G mutation in X-linked ID. Piton et al. [37] analyzed the exome sequence data of a large number of control X chromosomes from 2,443 males and 4,060 females recruited in the National Heart, Lung, and Blood (NHLBI) Exome Sequencing Project, considered as the "general population". Variations in a number of X-linked ID candidate genes, including MAGT1, were compiled in the exome variant server (EVS). The mutation p.V311G was detected in 13 out of 10,557 X chromosomes from the NHLBI cohort. Furthermore, one male carried a nonsense variant in MAGT1 (c.71G>C, p.Ser24*), further supporting doubts about its role in ID.
Recently Qiao et al. [8] described a novel 0.8 kb intronic duplication in MAGT1 that segregated with ID in five males from a family with X-linked ID. Exome sequencing also identified a single base-pair deletion in the last exon of the ATRX gene in the affected males. The patients showed dysmorphic features, seizures, chronic constipation, pruritus, soft crinkly skin of the palms and soles with excess creasing, and cracked, curved toe nails ( figure 3 ). The MAGT1 CNV had breakpoints in intron 3 of the largest isoform (hg18, ChrX: 77,009,644-77,010,488). It also mapped to the 3' UTR of the smallest isoform of MAGT1. This CNV did not cause alternative splicing based on cDNA profile, but included an alternative splicing site. Interestingly, the duplication caused a significant decrease in MAGT1 RNA and protein levels, which correlated with a reduced Mg 2+ influx capacity in EBV-transformed lymphoblasts from the affected individuals. These findings supported the hypothesis that a defective function of MAGT1 could contribute to the observed phenotype. However, the ATRX mutation, which also had a functional impact, seemed a more likely candidate as the cause of the ID [38] .
A B The MAGT1 CNV in this family was therefore proposed to be responsible for the abnormal skin phenotype (figure 3), as magnesium deficiency is known to affect negatively skin health [39] .
Discussion
Genetic disorders represent a potent avenue for the elucidation of complex physiological networks through examination of the molecular pathogenesis. Identification of genetic diseases ascribable to magnesium channels has not only greatly enhanced our knowledge of the basic mechanisms regulating systemic magnesium homeostasis, as in the case of hereditary forms of hypomagnesemia, but has also expanded our appreciation of fundamental, magnesium-dependent functions.
In particular analysis of the genetic changes so far identified in MAGT1 has provided molecular details of the role of magnesium in immunity, and warrants further investigation of its potential involvement in brain and skin health. The characterization of XMEN disease highlights the importance of the Mg 2+ influx driven by this channel in the T cell-mediated immune response, yet many questions remain unanswered. For example, it is puzzling that the presence of other magnesium channels, first and foremost TRPM7, does not seem to compensate for the MAGT1 defect, at least in CD4 + cells. It could be hypothesized that XMEN mutations do not affect solely Mg 2+ regulation, but also other (unknown) functions pertaining specifically to the MAGT1 protein; however, the recovery showed by XMEN patients upon Mg 2+ supplementation seems to rule out this possibility. An alternative explanation might lie in the different, tissue-specific signaling machinery that might be present: for instance, existing literature suggests that TRPM7 and MAGT1 could be "master regulators" of magnesium homeostasis in B and T lymphocytes, respectively [21] . This could also justify why the complete absence of MAGT1 does not appear to affect other tissues in XMEN patients. Moreover, it must be noted that patients bearing a different MAGT1 genetic change leading to dysfunction of Mg 2+ transport in B cells did not demonstrate immunodeficiency [8] . However, as affected subjects in that study did express the MAGT1 protein, it might be hypothesized that expression levels, albeit reduced, were sufficient to ensure the proper function of T lymphocytes.
On the other hand, the involvement of MAGT1 in X-linked ID remains controversial. The implication of the paralogue TUSC3 in autosomal ID appears well supported by the identification of additional, consanguineous families affected by mutations in this gene [37] ; yet the role of this protein in magnesium homeostasis is less well characterized, as are the functional consequences of the identified mutations at the cellular level. Analogously, the MAGT1 mutation identified by Molinari et al. [22] was not assessed at the functional level, and no further families were found wherein the association with X-linked ID could be confirmed. The absence of cognitive defects in XMEN patients, who have no detectable expression of MAGT1 protein, further argues against a connection with ID. As for the patients described in [8] , the concomitant presence of a mutation in the ATRX gene seemed a more likely explanation for the observed ID. Conversely, the same subjects presented with some unusual traits for the classical ATRX syndrome, in particular cutaneous problems, which were ascribed to the MAGT1 defect. Such interpretation awaits further confirmation from functional studies aimed at assessing the role of MAGT1-mediated Mg 2+ influx in skin. Intriguingly, XMEN patients had no skin problems. This seems to indicate that MAGT1 expression and/or function might be dispensable in different tissues, where other magnesium transporters could be more important. In addition, different transcripts of MAGT1 and associated mutations could be expressed differently in different tissues, resulting in tissue-specific effects.
In conclusion, recent findings concerning MAGT1-related genetic disorders have enriched the already variegated panel of magnesium functions in physiology and pathophysiology. In particular, an essential role for magnesium has been established in T cell-mediated immune responses, and possibly in skin. Most importantly, these results open the way to new therapeutic opportunities, as demonstrated by the successful treatment of XMEN patients by Mg 2+ supplementation, and testify once more to the vital importance of co-operation between basic scientists and clinicians. Disturbances in magnesium homeostasis, possibly through altered expression/function of its channels, have been implicated in a plethora of diseases, and Mg 2+ supplementation has been shown to be beneficial in the treatment of many of them. A deeper understanding of the molecular basis for the involvement of magnesium and its channels may further extend the significance of Mg 2+ therapies in the clinic, and may even identify new targets for more specific and effective therapies.
